1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Stentys
  6. News
  7. All News
    STNT   FR0010949404

STENTYS

(STNT)
End-of-day quote Euronext Paris  -  07-21
0.4600 EUR   -2.95%
2020Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020STENTYS : Financial Information for the First Quarter Of 2020
BU
2020STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020
CI
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about STENTYS
2020Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020STENTYS : Financial Information for the First Quarter Of 2020
BU
2020STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020
CI
2020STENTYS : Financial Information for the First Quarter of 2020
PU
2020STENTYS : 2019 Annual Results
PU
2019STENTYS : Convening of another Combined General Meeting on November 14, 2019
PU
2019STENTYS : 2019 half-year results
PU
2019Stentys Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2019
CI
2019STENTYS : Financial Information for the Third Quarter of 2019
PU
2019STENTYS : Financial Information for the First Half of 2019
PU
2019STENTYS : Convening of another Combined General Meeting on June 25, 2019
PU
2019STENTYS : Financial Information for the First Quarter of 2019
PU
2019Stentys S.A. Announces Revenue Results for the First Quarter 2019
CI
2019STENTYS : 2018 Annual results
PU
2019Stentys Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2..
CI
20192018 REVENUES : exceeding €10 million on a pro forma basis
PU
2019Stentys S.A. Announces Audited Revenue Results for the Fourth Quarter and Full Year End..
CI
2018STENTYS : Financial Information for the Third Quarter of 2018
PU
2018STENTYS S.A. Announces Consolidated Revenue Results for the Third Quarter and Nine Mont..
CI
2018STENTYS : 2018 half-year results
PU
2018STENTYS Announces Earnings Results for the Six Months Ended June 30, 2018
CI
2018STENTYS S.A. Announces Unaudited Consolidated Revenue Results for the Second Quarter an..
CI
2018STENTYS : Report on the General Meeting of June 4, 2018
PU
2018STENTYS : Convening of another Combined General Meeting on June 4, 2018
PU
2018STENTYS S.A. completed the acquisition of Minvasys.
CI
2018STENTYS S.A. Reports Revenue Results for the First Quarter Ended March 31, 2018
CI
2018STENTYS S.A. Announces Audited Consolidated Earnings Results for the Year Ended Decembe..
CI
2018STENTYS : RIGHTS ISSUE: 13 new shares @ 1.42 EUR for 28 existing shares
FA
2018STENTYS : announces plans to acquire MINVASYS
PU
2018STENTYS S.A. entered into an exclusive negotiations agreement to acquire Minvasys for €..
CI
2018STENTYS S.A. Announces Unaudited Revenue Results for the Fourth Quarter and Full Year o..
CI
2017STENTYS S.A. Announces the Pre-Commercialization of SERPENTIS, Its New Latest-Generatio..
CI
201712 OCTOBER 2017 : Revenues for the Third Quarter of 2017
PU
2017STENTYS S.A. Announces Unaudited Revenue Results for the Third Quarter and First Nine M..
CI
2017STENTYS S.A. Announces Earnings Results for the Six Months Ended June 30, 2017
CI
201702 OCTOBER 2017 : 2017 half-year results
PU
201727 JULY 2017 : STENTYS Completes Enrollment of the TRUNC Study
PU
201712 JULY 2017 : Revenues of €1.7 million in the second quarter of 2017
PU
2017STENTYS S.A. Announces Unaudited Revenue Results for the Second Quarter and First Half ..
CI
201722 JUNE 2017 : Report on the Combined Shareholders' Meeting of June 22, 2017
PU
201724 MAY 2017 : Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3..
PU
2017STENTYS S.A. cancelled the transaction announced on May 14, 2014
CI
2017STENTYS S.A. Announces Revenue Results for the First Quarter Ended March 31, 2017
CI
201703 APRIL 2017 : STENTYS is strengthening its Board by co-opting two new independent member..
PU
2017STENTYS S.A. Announces Executive Changes
CI
2017STENTYS S.A. Reports Earnings Results for the Year Ended December 31, 2016
CI
201712 JANUARY 2017 : 2016 Annual Revenues up 20% at €7.3 Million
PU
2017STENTYS Reports Revenue Results for the Fourth Quarter and Full Year of 2016
CI
201612 OCTOBER 2016 : STENTYS Reports 26% Year-over-Year Growth in Nine-Month 2016 Revenues
PU
2016STENTYS Announces Revenue Results for the Third Quarter and Nine Months Ended September..
CI
201615 SEPTEMBER 2016 : 2016 First-Half Results
PU
2016STENTYS Announces Consolidated Earnings Results for the Half-Year Ended June 30, 2016
CI
2016STENTYS Enrolls First Patient in Left Main Clinical Trial
CI
201612 JULY 2016 : STENTYS: 41% Increase in Revenues in the Second Quarter of 2016
PU
2016STENTYS Reports Revenue Results for the Second Quarter and Six Months Ended June 30, 20..
CI
201604 JULY 2016 : STENTYS: Appointment of Cardiovascular Device Veteran as New CEO
PU
2016STENTYS Appoints Christophe Lottin as CEO
CI
201604 JULY 2016 : STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO
PU
201608 JUNE 2016 : STENTYS Announces CE Marking of its longest Xposition stent
PU
201612 MAY 2016 : Convening of another Annual General Meeting on June 16, 2016
PU
2016STENTYS : Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Arter..
PU
2016STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Arte..
CI
2016STENTYS : Reports 2015 Annual Results (16 March 2016)
PU
2016STENTYS Reports Earnings Results for the Year Ended December 31, 2015
CI
2016STENTYS : 28 February 2016: Results of Self-Apposing Sirolimus-Eluting Stent Trial Publish..
PU
2016STENTYS : 29 February 2016: Results of Self-Apposing Sirolimus-Eluting Stent Trial Publish..
PU
2016STENTYS : RIGHTS ISSUE: 6 new shares @ 2.25 EUR for 13 existing shares
FA
2016STENTYS : 08 February 2016: Launch of the Commercialization of the first Self-Expanding Dr..
PU
2016STENTYS : 28 January 2016: First Intervention with the Self-Apposing Drug-Eluting Stent fo..
PU
2016STENTYS : Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues (13 January 20..
PU
2016STENTYS Announces Revenues Results for the Fourth Quarter and Full Year 2015
CI
2015STENTYS : 22 December 2015: 2016 Financial Agenda
PU
2015STENTYS : 09 December 2015: Enrollment Completion of MiStent Randomized Trial against Xien..
PU
2015STENTYS : Reports 84% Growth in Third-Quarter 2015 Revenues (15 October 2015)
PU
2015STENTYS : Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years (12 Octobe..
PU
1  2  3  4Next